Efficacy of Homoeopathy as an add-on therapy to standard conventional treatment in schizophrenia patients

Homoeopathy as adjunctive treatment to resperidone/ olanzipine in treatment resistant patients of schizophrenia: An open-label randomized placebo controlled trial - HomTRS

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/01/002321

Enrollment

Registered

2012-01-03

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Schizophrenia

Interventions

Intervention1: STANDARD THERAPY + homepathy medicines Homoeopathic medicines Antimonium crudum Apis mellifica Argentum nitricum Arsenicum album Aurum Metallicum Belladonna Bryonia alba Calcarea car

Eligibility

Inclusion criteria

Inclusion criteria: (a) Cases diagnosed as per EMEA 2003 criteria for treatment resistant schizophrenia patients i.e. Patients who have an inadequate response after two periods of at least at 6 weeks using neuroleptics of two drug types and with sufficient dosage (b) Age group between 18-45 yrs of any gender and from all socio economic background. (c) Those who sign written informed consent.

Exclusion criteria

Exclusion criteria: 1 Any systemic illness like Ischaemic heart disease, Hypertension, Diabetes mellitus etc. 2 Organic psychosis 3 Patients with H/o Space occupying Lesion (SOL) in brain. 4 Patients resistant to conventional medicine. 5 Patients who cannot comply with the study protocol 6 Lactating mother 7 Pregnant women 8 Patients taking any other conventional medicine other than the study medicine, (a wash out period of 2 weeks is to given) 9 Patient taken depot injections within last 3 months. 10 Patient received Electro convulsive therapy (ECT) within last three months.

Design outcomes

Primary

Measure	Time frame
•Change in symptom scores in comparison to Base line - PANSS and CGI-SCH rating scales at 12 months.Timepoint: 12 months	—

Secondary

Measure	Time frame
• Changes in the quality of life using WHO QOL-BREF, SUBI at 1 year of study between the groups at 12 months. • Changes in BPRS, HDRS score between the groups at 12 months • Changes in HDRS score between the groups at 12 months • To compare changes in sub groups: predominant positive & negative symptoms of schizophrenia using PASS between the groups at 12 months • To compare no. of acute exacerbations/recurrences/relapses in both the groups at 12 months • To compare no. of remissions in both the groups at 12 months • To compare no. of hospitalization/ days in hospital due to acute exacerbation in both the groups at 12 monthsTimepoint: 12 months	—

Measure

Time frame

• Changes in the quality of life using WHO QOL-BREF, SUBI at 1 year of study between the groups at 12 months. • Changes in BPRS, HDRS score between the groups at 12 months • Changes in HDRS score between the groups at 12 months • To compare changes in sub groups: predominant positive & negative symptoms of schizophrenia using PASS between the groups at 12 months • To compare no. of acute exacerbations/recurrences/relapses in both the groups at 12 months • To compare no. of remissions in both the groups at 12 months • To compare no. of hospitalization/ days in hospital due to acute exacerbation in both the groups at 12 monthsTimepoint: 12 months

—

Countries

India

Contacts

Public ContactDr Praveen oberai

Central Council for Research in Homoeopathy

oberai.praveen@gmail.com09811952274

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026